We are studying whether dapirolizumab pegol can improve symptoms in people with moderately to severely active systemic lupus erythematosus. This trial will also assess the safety of this new treatment when added to standard care.
We are studying the safety and immune response of the BEXSERO® vaccine in adults without a spleen. This trial compares their response to healthy individuals to ensure effective protection against meningococcal disease.
We are studying whether adding bacterial supplements to a combination of atezolizumab and bevacizumab helps patients with hepatocellular carcinoma who have not responded to first-line treatment. The trial also looks at the safety of this new approach.
We are studying a new combination therapy for patients with recurrent low-grade serous ovarian cancer to see if it helps them live longer and improves their quality of life compared to standard treatments.
We are studying whether a shorter 3-month antiplatelet therapy is as effective as the standard 12-month therapy after TAVI. The goal is to see if it reduces complications and bleeding risks.
We are studying whether methoxyflurane can effectively reduce pain and anxiety in adults facing oral emergencies. This trial will help us understand its benefits compared to a placebo.
We are studying the safety and effects of tolvaptan in infants and children with ARPKD. The trial aims to see if it helps reduce the need for kidney treatments.
We are studying whether zanidatamab combined with standard chemotherapy helps patients with advanced HER2-positive biliary tract cancer more than standard chemotherapy alone. This trial aims to evaluate its effectiveness and safety.
We are studying how corticosteroids are excreted to improve their detection in anti-doping controls. This research aims to help ensure fair play in sports.
We are investigating whether intravenous lidocaine can reduce abdominal pain in patients with chronic inflammatory bowel disease. Additionally, we will study how this treatment affects brain activity compared to healthy volunteers.
We are testing a new treatment called GTAEXS617 for patients with advanced solid tumors to see how safe it is and whether it can help fight the cancer. This study will look at the treatment alone and with standard therapies.
We are studying whether MDMA-assisted therapy can improve symptoms of PTSD in individuals who have not responded to other treatments. This trial also looks at how well this therapy works in a hospital setting.
We are studying the best dose of a new imaging agent for patients with tumors that express HER3. This research aims to improve how we visualize and understand tumor response to treatment.
We are testing a new medication, obefazimod, for people with moderately to severely active Crohn's disease who haven't responded to other treatments. The study aims to see if it is more effective and safe compared to a placebo.
We are studying a new treatment for patients with severe, hard-to-treat systemic lupus erythematosus. The trial aims to evaluate its safety, tolerability, and early signs of effectiveness.
We are investigating whether oral antibiotics can help reduce serious complications in patients with acute mesenteric ischemia. This study compares the effects of antibiotics to a placebo to see if they improve patient outcomes.
We are studying whether reducing immunosuppressive medication helps adults with psoriatic arthritis maintain stable disease activity. The trial also looks at the safety of this approach.
We are investigating a new imaging method using [18F]CETO to better classify types of primary aldosteronism. This may help improve diagnosis and treatment for affected individuals.
We are investigating if noradrenaline infusion is more effective than standard blood pressure management in preventing low blood pressure during noncardiac surgery. This study aims to improve patient safety and outcomes in the operating room.
We are studying whether Niraparib can help ovarian cancer patients with oligometastatic progression after surgery live longer without their cancer worsening. The trial will also assess safety and various health indicators.